Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Elicio Therapeutics has reported promising findings from preclinical studies of ELI-005, a protein subunit, lymph node targeting Covid-19 vaccine candidate.
Data showed that the candidate was able to trigger a ‘high magnitude’ T cell response and potent neutralising antibodies against Covid-19.
As antibody responses to the disease are short-lived, ELI-005’s induction of potent and long-lived antiviral T cells is expected to offer long-lasting protection, said Elicio.
Findings revealed up to 25-fold higher number of T cells, compared to benchmark vaccines, in peripheral blood, lung tissue and respiratory fluid, among other sites.